Clinical Trial Update: Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study [Phase 2]

View source ↗

Summary

Phase 2 trial investigating duvalizumab with neoadjuvant chemotherapy for Ib-IIIb non-small cell lung cancer; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ib-iiib Non-small Cell Lung Cancer

Drugs mentioned

• duvalizumab (duvalizumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Ib-IIIb NSCLC | Phase 2 | Status: UNKNOWN